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ABSTRACT 
A  simple,  selective  and  rapid  reversed  phase  high  performance  liquid  chromatographic  (RPHPLC)  method  for  the  analysis  of  esomeprazole  has  been 
developed and validated. The separation was achieved from HPLC Column (Prevail C8, 5µ, 4.6 mm x 150 mm) with a mobile phase consisting of HPLC grade 
acetonitrile and phosphate buffer solution (35:65) at a flow rate of 1ml/min with UV detection at 280nm. The method was specific and it was observed that no 
interference with diluents. The proposed method was accurate with 99.12% recovery for esomeprazole and precise (%RSD of area of system precision, % 
RSD of assay of method precision and Intermediate precision were found to be 0.09%, 0.21% and 0.43% respectively). From the linearity study the correlation 
coefficient is found to be 1.0000, which indicated that the method was linear over 10% to 150% range. The method was found robust for possible changes. 
Therefore, this method can be used as a more convenient and efficient option for the analysis of esomeprazole to establish the quality of the drug substance 
during routine analysis with consistent and reproducible results.  
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INTRODUCTION 
Esomeprazole magnesium trihydrate (ESO) is proton pump 
inhibitor  used  in  the  treatment  of  acid  related  disorders.
1 
ESO, a single optical S-isomer of omeprazole provides better 
acid control than current racemic proton pump inhibitors and 
has a convenient pharmacokinetic profile in comparison to 
omeprazole.
2 Several UV and RP-HPLC methods have been 
conducted for the estimation of ESO alone and combination 
with other drugs. 
3-11 
 Method validation is an indispensable necessity  from both 
regulatory and quality perspective.
12 As the analytical process 
varies  widely;  there  is  no  universal  regulation  for  method 
validation.  But United States Food and Drug Administration 
and  European  Commission  for  medicinal  products  have 
developed general non-mandatory guidelines.
13, 14 The prime 
purpose  for  validation  to  guarantee  that  method  and 
equipments  meet  the  requirements  to  ensure      safety, 
integrity, quality and strength of the product for use by the 
general  public.
15,  16  The  official  method  for  estimation  of 
esomeprazole  by  HPLC  is  included  in  United  States 
Pharmacopeia.  But  the  peak  retention  time  is  long,  so  the 
present work was undertaken with the aim to develop and 
validate  a  rapid  and  consistent  reversed-phase  high 
performance  liquid  chromatographic  method  in  which  the 
peak will appear in a short possible time according to ICH 
guideline.
17  
MATERIALS AND METHODS  
Reagents and chemicals 
HPLC  grade  Acetonitrile,  Methanol  and  85%  Ortho-
phosphoric acid were from Merck, Germany; analytical grade 
Monobasic,  Dibasic  and  Tri-basic  sodium  phosphate  were 
from  Scharlau,  Spain.  USP  Omeprazole  and  Esomeprazole 
Magnesium  Trihydrate  Reference  Standard  were  from  EP 
commission.  Esomeprazole  Magnesium  Trihydrate  USP 
working standard (WS) was from Glenmark generics   Ltd. 
India. Purified water was used for the analytical purpose. 
Instrumentation   
A Waters 2487 Module binary system with dual λ detector, 
USA was used. In this HPLC method we used Prevail C8, 5µ, 
4.6 mm  x  150  mm  column.  Analytical  Balance, pH  meter 
from Mettler, UK and Micropipette  from  Fischer,  Germany 
was used. 
METHOD DEVELOPMENT 
Preparation of Phosphate Buffer pH 7.6:  
0.725  g  of  monobasic  sodium  phosphate  and  4.472  g  of 
anhydrous dibasic sodium phosphate were dissolved in 300 
ml  of  purified  water.    Solution  was  diluted  with  purified 
water to 1000 ml.  250 ml of this solution was diluted to 1000 
ml.  
Preparation of mobile phase: 
35 volumes of HPLC grade acetonitrile was mixed with 65 
volumes of phosphate buffer (pH 7.6).  Solution was filtered 
through a 0.45 µm membrane filter.  
Preparation of Phosphate Buffer (pH 11):  
11 ml of 0.25 M tri-basic sodium phosphate was mixed with 
22 ml of 0.5 M dibasic sodium phosphate and diluted with 
water to 100 ml.  
Chromatographic conditions 
We used a 4.6 mm x 15 cm column in HPLC method that 
contains 5-µm packing L7 injection volume 20µl. Detection 
was carried out at 280 nm and the flow rate was 1 ml/min. 
Standard solution 
Accurately weighed 10.0 mg of omeprazole USP reference 
standard was taken into 200 ml volumetric flask.  10 ml of 
HPLC grade methanol was added to dissolve the standard and 
then 10 ml of buffer solution was added (pH 11). Solution 
was diluted to 200 ml with purified water. 
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Preparation of test solution: 
10.0  mg  of  the  test  sample  was  taken  into  a  200  ml 
volumetric flask. 10 ml of HPLC grade methanol was added 
to dissolve the sample and then 10 ml of buffer solution (pH 
11) was added.  Solution was diluted to 200 ml with purified 
water. 
System Suitability study 
The standard solution was used as system suitability solution 
and 20 µl of six replicate injections of standard solution was 
injected.  Chromatogram  was  recorded  &  system  suitability 
parameters  for  each  of  the  injection  and  %RSD  of  area 
(within 1.0 %) and %RSD of retention time (within 1.0 %) 
were calculated. 
METHOD VALIDATION  
System suitability 
The  relative  standard  deviation  (%RSD)  of  the  peak  area 
responses for esomeprazole from six replicate injections of 
standard solution should be  not more than 1.0%, The tailing 
factor,  theoretical  plate  counts  in  standard  solution    and 
%RSD of retention time should not be more than 2.0, less 
than 2000 and  within 1.0 % respectively. 
Specificity, linearity and system precision 
For  specificity  study  identification,  placebo  (diluents) 
interference  and  RT  ratio  of  sample  and  standard  were 
observed.  The  linearity  was  carried  out  by  observing  the 
correlation  coefficient  (r)  of  standard  solution.  System 
Precision  was  carried  out  by  performing  six  replicate 
injections at 100% of the test concentration and calculating 
the % RSD of the measured area.   
Method Precision 
Method precision was assessed by performing six replicate 
injections of the sample at 100% of the test concentration and 
% RSD of the assay result is calculated.  
Intermediate Precision (Ruggedness) 
Intermediate precision or ruggedness study of an analytical 
method  is  the  degree  of  reproducibility  of  the  test  results 
obtain by the analysis of the same samples under a variety of 
normal  test  conditions  i.e.  different  instrument,  analysts, 
column,  days,  laboratories  etc.  Sample  for  intermediate 
precision was assessed by performing replicate assays (n=6) 
of sample at 100% of the test concentration and difference 
between  mean  assay  of  two  different  analysts.  %RSD  of 
assay  results  (twelve  assay  results)  was  calculated  in  this 
study. 
Accuracy 
Study was carried out over a range of 50%, 80%, 90%, 100%, 
120%,  130%  and  150  %(3  replicates  each    of  the  total 
analytical procedure) of   test concentration. The % recovery 
and  RSD  of  %  recovery  of  each  concentration  were 
measured. 
Range 
Data  generated  in  linearity,  precision  and  accuracy  were 
considered  for  establishing  the  range  of  the  analytical 
method. 
Robustness 
Robustness of the method was investigated by changing flow 
rate (± 2%), column temperature (± 5ºC), ratio of components 
of mobile phase and pH (±0.2). 
Stability Study 
The  solution  stability  experiments  were  performed  under 
room temperature at intervals of 0 hr, 6 hrs, 12 hrs, 18 hrs, 24 
hrs, 30 hrs and 48 hrs.  
 
RESULTS AND DISCUSSION  
System suitability  
System suitability is an integral part of analytical procedures. 
In optimized chromatographic conditions %RSD of area of 
Omeprazole and %RSD of retention time were found 0.22, 
0.07 respectively. Average tailing factor and theoretical plate 
count were 1.29 and 8056 respectively .Table-1 shows the 
system  suitability  data.  The  results  from  six  consecutive 
injections of the standard solution indicates a good system for 
analysis.  
Specificity   
Specificity  of  an  analytical  method  is  its  ability  to  assess 
unequivocally the analyte in the presence of components that 
may  be  expected  to  be  present.  Lack  of  specificity  of  an 
individual analytical procedure may be compensated by other 
supporting  analytical  procedures.
18  From  the  specificity 
study,  it  was  observed  that  the  chromatogram  for 
esomeprazole  sample  with  omeprazole  standard  show 
positive response and blank (diluents) has no response.  The 
RT  ratio  of  sample  &  standard  was  1.0  (limit  0.95-1.05) 
which also indicated the specificity of the method. 
Linearity 
The linearity of an analytical method is its ability to elicit test 
results  directly  proportional  to  the  concentration  of  the 
analyte  in  samples  within  given  range.
19  Linearity  of  the 
method  was  evaluated  from  the  correlation  coefficient  of 
calibration curves that were constructed from mean peak area 
of omeprazole at different concentrations level (10%, 20%, 
30%,  50%,  80%,  90%,  100%,  120%,  130%  and  150%). 
Correlation  coefficient  was  1.0000  which  proved  that  the 
method was linear. (Table-2) (Figure-1).   
System precision  
System Precision was carried out by performing six replicate 
injections at 100% of the test concentration and calculating 
the % RSD of the measured area.  . From the data ( table-3) it 
was observed that the % RSD of area is 0.09% which is well 
within  the  acceptance  limit  of  1.0%.  Hence  the  system  is 
precise. 
Method Precision 
The % RSD of six sample assay results was found 0.21 % 
which was within the acceptance limit. (Table-4) 
Intermediate precision or ruggedness 
The  intermediate  precision  of  the  method  was  evaluated 
using different analyst and different instrument in the same 
laboratory. Assay results by two different analysts at different 
days have been found very much close to each other and with 
a difference of only 0.74 % and the % RSD of two analysts 
(12  samples)  is  0.43%  which  is  well  within  acceptance 
criteria.  So  the  method  can  be  considered  to  be  rugged 
enough. (Table-5) 
Accuracy 
The accuracy of an analytical method is the closeness of test 
results obtained by that method to the true value. The average 
% recovery at different accuracy label was found 99.12 %, 
and % RSD for individual % recovery meets the acceptance 
criteria. Hence the method is Accurate. (Table-6) 
Range 
The specified range is normally derived from linearity studies 
and depends on the intended application of the procedure. It 
is  established  by  confirming  that  the  analytical  procedure 
provides  an  acceptable  degree  of  linearity,  accuracy  and 
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analyte  within  the  extremes  of  the  specified  range  of  the 
analytical procedure.  
Based  on  the  linearity,  precision  and  accuracy  results,  the 
range of the method was determined as 50% to 150% of the 
target concentration. (Table-7) 
Robustness 
The robustness of an analytical method is a measure of its 
capacity  to  remain  unchanged  by  little  but  intentional 
variation in method parameters and provides an indication of 
its  reliability  during  normal  usage.
20  Robustness  of  the 
method  was  investigated  by  changing  flow  rate  (±  2%), 
changing column temperature (± 5ºC), ratio of components of 
mobile phase, changing pH (±0.2).(Table-8) 
From the above results it is clear that the system suitability 
criteria meet with the acceptance limit. Hence the method is 
robust. 
Stability study 
From the solution stability study it was observed that the test 
sample  solution  is  found  to  be  stable  up  to  48  hours  at 
ambient condition. (Table-9) 
CONCLUSION 
The  method  adopted  for  estimation  of  Esomeprazole  by 
HPLC is precise, linear, accurate, rugged and robust enough. 
The sample solution was found to be stable up to 48 hours at 
ambient condition. Hence this method can be considered for 
routine  use  to  establish  the  quality  of  the  drug  substance 
during  routine  analysis  with  consistent  and  reproducible 
results. 
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Table – 1: System suitability Study 
Injection  Area  Retention Time  USP Tailing Factor  Theoretical Plate 
Number 
1.  1449028  5.95  1.29  7943 
2.  1446999  5.94  1.29  8085 
3.  1451887  5.94  1.30  8072 
4.  1454273  5.94  1.30  8068 
5.  1455190  5.94  1.29  8063 
6.  1453127  5.93  1.30  8106 
Average ( n=6 )  1451751  5.94  1.29  8056 
SD  3165.29  0.01  -  - 
%RSD  0.22  0.07  -  - 
Acceptance Criteria  NMT 2.0%  NMT 1.0%  NMT 2.0  NLT 2000 
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Table – 2: Linearity study 
Level  Concentration in % 
( X  -axis ) 
Area 
( Y - axis ) 
1.  10  128821 
2.  20  260444 
3.  30  381725 
4.  50  645212 
5.  80  1013319 
6.  90  1143045 
7.  100  1270226 
8.  120  1532850 
9.  130  1658616 
10.  150  1916998 
Correlation coefficient (r)  1.0000 
Acceptance Criteria : Correlation coefficient, r = ³ ³ ³ ³ 0.9990 
 
Table 3: System precision study 
Injection  Retention Time (mins)  Area 
1.  5.96  1299248 
2.  6.00  1299052 
3.  5.97  1297044 
4.  5.96  1299421 
5.  5.96  1299162 
6.  5.96  1300751 
Average  5.97  1299113 
SD  0.02  1190.21 
% RSD  0.30  0.09 
 
Table 4: Method precision 
Sr. No.  Wt. of Standard  Area of Standard  Wt. of Sample  Area of Sample  % of Assay 
1. 
10.05 
 
1449286 
 
10.01  1300037  100.88 
2.  10.00  1299925  100.97 
3.  10.03  1298730  100.58 
4.  10.02  1299260  100.72 
5.  10.02  1300562  100.82 
6.  10.01  1304228  101.20 
Average (n=6)  100.86 
SD  0.22 
%RSD  0.21 
Acceptance Criteria: %RSD of Assay NMT 2.0% 
 
Table-5: Table for Intermediate precision or Ruggedness study 
Analyst Name  Analyst 1  Analyst 2 
Location  Instrument Room-I  Instrument Room-I 
Instrument  HPLC System I  HPLC System II 
Date of analysis  09.02.10  11.02.10 
Area of Std.  1449286  1446769 
Sr. 
No. 
Weight of sample 
(mg)  Area  Assay (%)  Weight of sample 
(mg)  Area  Assay (%) 
1.  10.01  1300037  100.88  9.99  1290286  100.10 
2.  10.00  1299925  100.97  10.00  1295512  100.40 
3.  10.03  1298730  100.58  10.05  1295966  99.94 
4.  10.02  1299260  100.72  10.03  1295176  100.08 
5.  10.02  1300562  100.82  10.04  1293823  99.87 
6.  10.01  1304228  101.20  10.01  1295698  100.32 
 
Mean Assay (n=6)  100.86  Mean Assay (n=6)  100.12 
Standard deviation n=6  0.22  Standard deviation n=6  0.21 
% RSD (n=6)  0.21  % RSD (n=6)  0.21 
i. Difference (Difference between mean assay of Two different analysts) → 0.74% 
ii. %RSD of assay results (twelve assay results) → 0.43% 
Acceptance Criteria: i. ± 2% Difference of each other 
ii. %RSD of assay results (twelve assay results): NMT 2.0% 
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Table-6: Accuracy study 
Level  Weight of sample (mg)  Area of Sample  % of Recovery  % RSD of Individual 
recovery 
50% 
4.98  637834  99.49 
0.32  4.99  640901  99.76 
5.00  638058  99.12 
80% 
7.95  1010522  98.73 
0.86  7.98  1013916  98.69 
8.02  1034520  100.19 
90% 
8.97  1145799  99.22 
0.27  8.99  1144773  98.91 
9.00  1143363  98.68 
100% 
10.00  1274461  98.99 
0.12  9.99  1275038  99.14 
9.96  1272459  99.24 
120% 
11.98  1526959  99.00 
0.06  11.99  1527580  98.96 
12.00  1530572  99.07 
130% 
12.98  1652022  98.86 
0.28  12.96  1651859  99.00 
12.98  1661019  99.40 
150% 
14.95  1911661  99.26 
0.25  15.00  1911226  98.97 
14.99  1906121  98.77 
Average (n = 21)  99.12  - 
Standard Deviation (SD)  0.37  - 
%Relative Standard Deviation (%RSD)  0.37  - 
Acceptance Criteria : % Recovery: (98 –102)% and %RSD:  NMT 2.0% 
 
Table-7: Range study 
Parameter  Concentration Range  Acceptance limit  Result 
Linearity  10 % to 150%  R NLT 0.9990  R =1.0000 
Method Precision  100%  %RSD of Assay NMT 2.0%  0.21% 
Intermediate 
Precision 
100%  %RSD of two analyst NMT 2.0 
± 2% Difference of each other 
% RSD of 2 analyst =0.43% 
Difference of assay =0.74% 
Accuracy  50% to 150%  % Recovery: (98 –102)% and %RSD:  
NMT 2.0% 
% Recovery: 99.12 %, 
%RSD:  NMT 2.0% 
 
Table-8: Data of System suitability (Robustness study) 
Parameter  % RSD of Area  Theoretical Plate 
Number 
Tailing Factor 
Flow rate + 2%  0.08%  7976  1.31 
Flow rate - 2%  0.16%  8416  1.33 
Column Temperature at 30˚C  0.08%  8537  1.30 
Column Temperature at 35˚C  0.05%  8758  1.32 
Buffer : HPLC grade Acetonitrile (63 : 37)  0.09%  8064  1.34 
Buffer : HPLC grade Acetonitrile (67 : 33)  0.11%  8726  1.35 
Buffer pH 7.40  0.05%  8338  1.35 
Buffer pH 7.80  0.07%  7922  1.33 
 
Table-9: Solution stability study 
Duration of Sample Solution (Hour)  % of Assay  % Difference from initial 
At initial (0 hr)  100.47  - 
After 6 hrs  100.81  - 0.34 
After 12 hrs  100.88  - 0.41 
After 18 hrs  100.90  - 0.43 
After 24 hrs  99.92  0.55 
After 30 hrs  100.07  0.40 
After 48 hrs  100.11  0.36 
% RSD  0.42  - 
Acceptance Criteria: ≤ 2.0% change from initial 
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Figure-1: Graphical Representation of Linearity 
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Figure 2:  Representative HPLC chromatogram of Esomeprazole 
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